CVSA

Covista Inc. (CVSA) - Q3 Fiscal 2026 10-Q Summary

Business Context and Reporting Period

This filing covers the third quarter of fiscal year 2026, ended March 31, 2026. Covista Inc. (formerly Adtalem Global Education) operates as a leading healthcare educator in the U.S. through three reportable segments: Chamberlain University, Walden University, and the Medical and Veterinary schools (AUC, RUSM, RUSVM). The company reports on a fiscal year ending June 30.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Consolidated revenue increased 4.5% in Q3 and 9.1% for the nine months ended March 31, 2026. Growth was driven by higher enrollment and tuition rates across all segments. Note: Walden revenue was impacted by a one-week academic calendar shift, moving $18.0 million of revenue from Q3 to Q2.
• Net Income Decline: Net income decreased 31.6% in Q3 to $41.6 million. This was primarily due to a $16.3 million loss from discontinued operations (related to DeVry University litigation/settlements) and increased operating costs (labor, marketing) to support enrollment growth.
• Debt Restructuring: On March 2, 2026, Covista refinanced its debt structure. It incurred a new $510.0 million Term Loan B (maturing 2033) and repaid the remaining $405.0 million of Senior Secured Notes due 2028. This resulted in a $3.8 million loss on debt extinguishment recorded in interest expense.
• Share Repurchases: The company repurchased 637,538 shares in Q3 at an average price of $103.04. As of March 31, 2026, $661.8 million remained available under the current $750 million authorization.

Guidance, Outlook, and Risks

• Enrollment Trends: Total student enrollment at Walden increased 12.3% year-over-year. Medical and Veterinary enrollment increased 4.1% for the January 2026 semester. Chamberlain enrollment remained relatively flat (-0.7% to +0.5% depending on session).
• Regulatory Environment: Covista operates under provisional certification for Title IV financial aid programs due to a composite score below 1.5. The company maintains $202.6 million in surety-backed letters of credit for the U.S. Department of Education (ED). ED has provisionally recertified PPAs for Chamberlain, Walden, and AUC through late 2028.
• Borrower Defense to Repayment (BDR): The company has received thousands of BDR claims across its institutions. Management believes none properly state an eligible claim for loan forgiveness, and no recoupment notices have been received as of the filing date.
• Legislative Changes: The "One Big Beautiful Bill Act" (OBBBA) was signed in July 2025, restoring 2019 BDR regulations and delaying 2022 regulations until 2035. It also introduced "Do No Harm" provisions regarding program earnings.

Investor Verification Checklist

• Discontinued Operations Impact: Verify the magnitude of the $16.3 million loss from discontinued operations and the status of ongoing DeVry University litigation.
• Walden Revenue Timing: Confirm the impact of the one-week academic shift on Q3 comparability; adjusted revenue would have been higher.
• Debt Covenants: Review the new Term Loan B terms (SOFR + 2.25%) and ensure compliance with the Total Net Leverage Ratio covenant (max 3.25:1).
• Regulatory Compliance: Monitor ED's final decisions on provisional recertification for RUSM (application pending) and the potential impact of new "Do No Harm" regulations on program eligibility.
• Shareholder Returns: Track the execution of the remaining $661.8 million share repurchase authorization against market conditions.